Holothurin A Inhibits RUNX1-Enhanced EMT in Metastasis Prostate Cancer via the Akt/JNK and P38 MAPK Signaling Pathway
Marine Drugs · 03.06.2023 · 21 (6) · 345
DOI: 10.3390/md21060345 ↗Kurz gefasst
Fachartikel in der Zeitschrift Marine Drugs, online erschienen am 03.06.2023. Verfasst von Sirorat Janta und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy, Faculty of Science, Mahidol University, Bangkok 10400, Thailand. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Prostatic Neoplasms. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Agricultural Research Development Agency (Public Organization) Thailand, Mahidol University Basic Research Fund: fiscal year 2021 to Kulathida Chaithirayanon, Central Instrument Facility, Faculty of Science, Mahidol University.
Abstract (Originalsprache)
Due to the challenge of prostate cancer (PCa) management, there has been a surge in efforts to identify more safe and effective compounds that can modulate the epithelial–mesenchymal transition (EMT) for driving metastasis. Holothurin A (HA), a triterpenoid saponin isolated from Holothuria scabra, has now been characterized for its diverse biological activities. However, the mechanisms of HA in EMT-driven metastasis of human PCa cell lines has not yet been investigated. Moreover, runt-related transcription factor 1 (RUNX1) acts as an oncogene in prostate cancer, but little is known about its role in the EMT. Thus, the purpose of this study was to determine how RUNX1 influences EMT-mediated metastasis, as well as the potential effect of HA on EMT-mediated metastasis in endogenous and exogenous RUNX1 expressions of PCa cell lines. The results demonstrated that RUNX1 overexpression could promote the EMT phenotype with increased EMT markers, consequently driving metastatic migration and invasion in PC3 cell line through the activation of Akt/MAPK signaling pathways. Intriguingly, HA treatment could antagonize the EMT program in endogenous and exogenous RUNX1-expressing PCa cell lines. A decreasing metastasis of both HA-treated cell lines was evidenced through a downregulation of MMP2 and MMP9 via the Akt/P38/JNK-MAPK signaling pathway. Overall, our approach first demonstrated that RUNX1 enhanced EMT-driven prostate cancer metastasis and that HA was capable of inhibiting the EMT and metastatic processes and should probably be considered as a candidate for metastasis PCa treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anatomy, Faculty of Science, Mahidol University, Bangkok 10400, Thailand.
- Chulabhorn International College of Medicine, Thammasat University, Pathumthani 12120, Thailand.
- Chakri Naruebodindra Medical Institute, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok 10540, Thailand.
- Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Songkhla 09112, Thailand.
- Department of Physiology, Faculty of Science, Mahidol University, Bangkok 10400, Thailand.
- Department of Anatomy, Faculty of Medicine, Srinakharinwirot University, Wattana, Bangkok 10110, Thailand.
ORCID-Profile: Pornpun Vivithanaporn, Anuchit Plubrukarn, Kulathida Chaithirayanon
Förderung
- the Agricultural Research Development Agency (Public Organization) Thailand
- Mahidol University Basic Research Fund: fiscal year 2021 to Kulathida Chaithirayanon
- Central Instrument Facility, Faculty of Science, Mahidol University
- Agricultural Research Development Agency (Public Organization) Thailand
- Mahidol University Basic Research Fund
- Faculty of Science, Mahidol University, Thailand
Zitieren
APA
Janta, S., Pranweerapaiboon, K., Vivithanaporn, P., Plubrukarn, A., Chairoungdua, A., Prasertsuksri, P., Apisawetakan, S., & Chaithirayanon, K. (2023). Holothurin A Inhibits RUNX1-Enhanced EMT in Metastasis Prostate Cancer via the Akt/JNK and P38 MAPK Signaling Pathway. Marine Drugs, 21(6), 345. https://doi.org/10.3390/md21060345
Vancouver
Janta S, Pranweerapaiboon K, Vivithanaporn P, Plubrukarn A, Chairoungdua A, Prasertsuksri P, et al. Holothurin A Inhibits RUNX1-Enhanced EMT in Metastasis Prostate Cancer via the Akt/JNK and P38 MAPK Signaling Pathway. Marine Drugs. 2023;21(6):345. doi:10.3390/md21060345
BibTeX
@article{Janta2023,
author = {Janta, Sirorat and Pranweerapaiboon, Kanta and Vivithanaporn, Pornpun and Plubrukarn, Anuchit and Chairoungdua, Arthit and Prasertsuksri, Prachayaporn and Apisawetakan, Somjai and Chaithirayanon, Kulathida},
title = {Holothurin A Inhibits RUNX1-Enhanced EMT in Metastasis Prostate Cancer via the Akt/JNK and P38 MAPK Signaling Pathway},
journal = {Marine Drugs},
year = {2023},
volume = {21},
number = {6},
pages = {345},
doi = {10.3390/md21060345}
}
EUVIMED